Correction to: The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes
Crossref DOI link: https://doi.org/10.1007/s40273-020-00885-8
Published Online: 2020-01-21
Published Print: 2020-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Panattoni, Laura
Brown, Paul M.
Ao, Braden Te
Webster, Mark
Gladding, Patrick
Text and Data Mining valid from 2020-01-21
Version of Record valid from 2020-01-21
Article History
First Online: 21 January 2020
Free to read: This content has been made available to all.